Drug-induced parkinsonism

Handbook of Clinical Neurology

Volumn 84, Issue , 2007, Pages 399-416

  Micheli, Federico Eduardo ^a   Cersósimo, María Graciela ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 67649369301     PISSN: 00729752     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0072-9752(07)84051-6     Document Type: Chapter

References (148)

1. Akbostanci M.C., Atbasoglu E.C., and Balaban H. Tardive dyskinesia, mild drug-induced dyskinesia, and drug-induced parkinsonism: risk factors and topographic distribution. Acta Neurol Belg 99 (1999) 176-181
2. Allam M.F., Campbell M.J., Hofman A., et al. Smoking and Parkinson's disease: systematic review of prospective studies. Mov Disord 19 (2004) 614-621
3. Ananth J., Samra D., and Kolivakis T. Amelioration of drug-induced Parkinsonism by ECT. Am J Psychiatry 136 8 (1979) 1094
4. Arblaster L.A., Lakie M., Mutch W.J., et al. A study of the early signs of drug induced parkinsonism. J Neurol Neurosurg Psychiatry 56 3 (1993) 301-303
5. Aronson T.A. Persistent drug-induced parkinsonism. Biol Psychiatry 20 7 (1985) 795-798
6. Avorn J., Bohn R.L., Mogun H., et al. Neuroleptic drug exposure and treatment of parkinsonism in the elderly: a case-control study. Am J Med 99 1 (1995) 48-54
7. Awad A.G., and Voruganti L.N. Impact of atypical antipsychotics on quality of life in patients with schizophrenia. CNS Drugs 18 (2004) 877-893
8. Ayd F.J. A survey of drug-induced extrapyramidal reactions. JAMA 175 (1961) 1054-1060
9. Baldereschi M., Di Carlo A., Rocca W.A., et al. Parkinson's disease and parkinsonism in a longitudinal study: two-fold higher incidence in men. ILSA Working Group. Italian Longitudinal Study on Aging. Neurology 55 9 (2000) 1358-1363
10. Bashford G., and Bradd P. Drug-induced Parkinsonism associated with dysphagia and aspiration: a brief report. J Geriatr Psychiatry Neurol 9 3 (1996) 133-135
11. Becker G., Seufert J., Bogdahn U., et al. Degeneration of substantia nigra in chronic Parkinson's disease visualized by transcranial color-coded real-time sonography. Neurology 45 (1995) 182-184
12. Ben Shachar D., Livne E., Spanier I., et al. Iron modulates neuroleptics induced effects related to the dopaminergic system. Isr J Med Sci 29 (1993) 587-592
13. Ben Shachar D., Livne E., Spanier I., et al. Typical and atypical neuroleptics induce alteration in blood brain barrier and brain 59Fe c13 uptake. J Neurochem 62 (1994) 112-118
14. Berg D., Becker G., Zeiler B., et al. Vulnerability of the nigrostriatal system as detected by transcranial ultrasound. Neurology 53 (1999) 1026-1031
15. Berg D., Jabs B., Merschdorf U., et al. Echogenicity of substantia nigra determined by transcranial ultrasound correlates with severity of parkinsonian symptoms induced by neuroleptic therapy. Biol Psychiatry 50 (2001) 463-467
16. Bharucha N.E., Bharucha E.P., Bharucha A.E., et al. Prevalence of Parkinson's disease in the Parsi community of Bombay, India. Arch Neurol 45 12 (1988) 1321-1323
17. Bhatia K., Daniel S.E., and Marsden C.D. Orofacial dystonia and rest tremor in a patient with normal brain pathology. Mov Disord 8 3 (1993) 361-362
18. Binder R.L., and Jonelis F.J. Seborrheic dermatitis in neuroleptic-induced parkinsonism. Arch Dermatol 119 6 (1983) 473-475
19. Bloomquist J., King E., Wright A., et al. 1-methyl-4-phenylpyridinium-like neurotoxicity of a pyridinium metabolite derived from haloperidol; cell culture and neurotransmitter uptake studies. J Pharmacol Exp Ther 270 (1994) 822-830
20. Borison R.L., Hitri A., Blowers A.J., et al. Antipsychotic drug action: clinical, biochemical, and pharmacological evidence for site specificity of action. Clin Neuropharmacol 6 (1983) 137-150
21. Bower J.H., Maraganore D.M., McDonnell S.K., et al. Incidence and distribution of parkinsonism in Olmsted County, Minnesota, 1976-1990. Neurology 52 6 (1999) 1214-1220
22. Bower J.H., Dickson D.W., Taylor L., et al. Clinical correlates of the pathology underlying parkinsonism: a population perspective. Mov Disord 17 5 (2002) 910-916
23. Brooks D.J. Detection of preclinical Parkinson's disease with PET. Geriatrics 46 Suppl 1 (1991) 25-30
24. Brown K.W., Wardlaw J.M., White T., et al. Caudate nucleus area in drug-induced parkinsonism. Acta Psychiatr Scand 94 5 (1996) 348-351
25. Brucke T., Wober C., Podreka I., et al. D2 receptor blockade by flunarizine and cinnarizine explains extrapyramidal side effects. A SPECT study. J Cereb Blood Flow Metab 15 (1995) 513-518
26. Bulens C., Meerwaldt J.D., van der Wildt G.J., et al. Visual contrast sensitivity in drug-induced Parkinsonism. J Neurol Neurosurg Psychiatry 52 3 (1989) 341-345
27. Caligiuri M.P., Bracha H.S., and Lohr J.B. Asymmetry of neuroleptic-induced rigidity: development of quantitative methods and clinical correlates. Psychiatry Res 30 3 (1989) 275-284
28. Caligiuri M.R., Jeste D.V., and Lacro J.P. Antipsychotic-induced movement disorders in the elderly: epidemiology and treatment recommendations. Drugs Aging 17 5 (2000) 363-384
29. Cardoso F. Treatment of Parkinson disease. Arq Neuropsiquiatr 53 1 (1995) 1-10
30. Carlsson A. The occurrence, distribution and physiological role of catecholamines in the nervous system. Pharmacol Rev 11 (1959) 490-493
31. Casey D.E. Neuroleptic drug-induced extrapyramidal syndromes and tardive dyskinesia. Schizophr Res 4 (1991) 109-120
32. Chabolla D.R., Maraganore D.M., Ahlskog J.E., et al. Drug-induced parkinsonism as a risk factor for Parkinson's disease: a historical cohort study in Olmsted County, Minnesota. Mayo Clin Proc 73 8 (1998) 724-727
33. Chaisewikul R., Baillie N., and Marson A.G. Calcium antagonists as an add-on therapy for drug-resistant epilepsy. Cochrane Database Syst Rev 4 (2001) CD002750 Review
34. Chiueh C.C., Miyake H., and Peng T. Role of dopamine autoxidation, hydroxyl radical generation and calcium overload in underlying mechanisms involved in MPTP induced Parkinsonism. Adv Neurol 60 (1993) 251-258
35. Chouza C., Scaramelli A., Caamano J.L., et al. Parkinsonism, tardive dyskinesia, akathisia, and depression induced by flunarizine. Lancet 7 1 (1986) 1303-1304
36. Crane G.E., and Smeets R.A. Tardive dyskinesia and drug therapy in geriatric patients. Arch Gen Psychiatry 30 (1974) 341-343
37. Curran T., and Morgan J.I. Fos: an immediate-early transcription factor in neurons. J Neurobiol 26 (1995) 403-412
38. Delay J., and Deniker P. Chlorpromazine and neuroleptic treatment in psychiatry. J Clin Exp Psychopathol 17 (1956) 19-24
39. Delay J., Deniker P., and Harl J.M. Utilisation en therapeutique psychiatrique d'une phenothiazine d'action centrale elective (4560 RP). Ann Med Psychol 110 (1952) 112-117
40. Dell'Agnello G., Ceravolo R., Nuti A., et al. SSRIs do not worsen Parkinson's disease: evidence from an open-label, prospective study. Clin Neuropharmacol 24 (2001) 221-227
41. Dick R.S., and Barold S.S. Diltiazem-induced parkinsonism. Am J Med 87 1 (1989) 95-96
42. Dorfman-Etrog P., Hermesh H., Prilipko L., et al. The effect of vitamin E addition to acute neuroleptic treatment on the emergence of extrapyramidal side effects in schizophrenic patients: an open label study. Eur Neuropsychopharmacol 9 (1999) 475-477
43. Ehringer H., and Hornykiewicz O. Verteilung von noradrenalen und dopamine (3-hydroxytyramine) im gehirn des menschen und ihr berhatten bei erkrankingen des extrapyramidalen systems. Klin Wochenschr 24 (1960) 1236-1239
44. Errea-Abad J.M., Ara-Callizo J.R., and Aibar-Remon C. Drug-induced parkinsonism. Clinical aspects compared with Parkinson disease. Rev Neurol 27 155 (1998) 35-39
45. Faber R., and Trimble M.R. Electroconvulsive therapy in Parkinson's disease and other movement disorders. Mov Disord 6 4 (1991) 293-303
46. Fahn S., and Mayeux R. Unilateral Parkinson's disease and contralateral tardive dyskinesia: a unique case with successful therapy that may explain the pathophysiology of these two disorders. J Neural Transm Suppl 16 (1980) 179-185
47. Fann W.E., and Lake C.R. Amantadine versus trihexyphenidyl in the treatment of neuroleptic-induced parkinsonism. Am J Psychiatry 133 8 (1976) 940-943
48. Farde L., NordstriSm A.L., Wiesel F.A., et al. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy inpatients treated with classical neuroleptics and clozapine: relation to extrapyramidal side effects. Arch Gen Psychiatry 49 (1992) 538-544
49. Fernandez Pardal M., Fernandez Pardal J., and Micheli F. Aggravation of Parkinson's disease by cinnarizine. J Neurol Neurosurg Psychiatry 51 (1988) 158-159
50. Fleischhacker W. Negative symptoms in patients with schizophrenia with special reference to the primary versus secondary distinction. Encephale 26 (2000) 12-14 Spec No 1
51. Freyhan F.A. Therapeutic implications of differential effects of new phenothiazine compounds. Am J Psychiatry 115 (1959) 577-585
52. Friedman J.H. Drug-induced movement disorders. In: Weiner W.J., and Lang A.E. (Eds). Movement Disorders: a Comprehensive Survey (1989), Futura Publishing Co. Inc, Mount Kisco, New York 41-83
53. Frost J.J., Rosier A.J., Reich S.G., et al. Positron emission tomographic imaging of the dopamine transporter with 11C-WIN 35,428 reveals marked declines in mild Parkinson's disease. Ann Neurol 34 (1993) 423-431
54. Garcia-Ruiz P.J., Garcia de Yebenes J., Jimenez-Jimenez F.J., et al. Parkinsonism associated with calcium channel blockers: a prospective follow-up study. Clin Neuropharmacol 15 (1992) 19-26
55. Gershanik O.S. Drug-induced parkinsonism in the aged. Recognition and prevention. Drugs Aging 5 2 (1994) 127-132
56. Gibb W.R. Melanin, tyrosine hydroxylase, calbindin and substance P in human midbrain and substantia nigra in relation to nigrostriatal projections and differential neuronal susceptibility in Parkinson's disease. Brain Res 581 (1992) 283-291
57. Gil-ad I., Shtaif B., Shiloh R., et al. Evaluation of the neurotoxic activity of typical and atypical neuroleptics: relevance to iatrogenic extrapyramidal symptoms. Cell Mol Neurobiol 21 (2001) 705-716
58. Giladi N., Kao R., and Fahn S. Freezing phenomenon in patients with parkinsonian syndromes. Mov Disord 12 3 (1997) 302-305
59. Glazer W.M., Naftolin F., Moore D.C., et al. The relationship of circulating estradiol to tardive dyskinesia in men and postmenopausal women. Psychoneuroendocrinology 8 (1983) 429-434
60. Goswami U., Dutta S., Kuruvilla K., et al. Electroconvulsive therapy in neuroleptic-induced parkinsonism. Biol Psychiatry 26 (1989) 234-238
61. Hall R.A., Jackson R.B., and Swaim J.M. Neurotoxic reactions resulting from chlorpromazine administration. JAMA 161 (1956) 214-218
62. Hanin B., Lerner Y., and Srour N. An unusual effect of ECT on drug-induced parkinsonism and tardive dystonia. Convuls Ther 11 (1995) 271-274
63. Hansen T.E., Brown W.L., Weigel R.M., et al. Underrecognition of tardive dyskinesia and drug-induced parkinsonism by psychiatric residents. Gen Hosp Psychiatry 14 5 (1992) 340-344
64. Hardie R.J., and Lees A.J. Neuroleptic-induced Parkinson's syndrome: clinical features and results of treatment with levodopa. J Neurol Neurosurg Psychiatry 51 (1988) 850-854
65. Hoffman W.F., Ballard L., Turner E.H., et al. Three-year follow-up of older schizophrenics: extrapyramidal syndromes, psychiatric symptoms, and ventricular brain ratio. Biol Psychiatry 30 9 (1991) 913-926
66. Horiguchi J., and Nishimatsu O. Usefulness of antiparkinsonian drugs during neuroleptic treatment and the effects of clonazepam on akathisia and parkinsonism occurred after antiparkinsonian drug withdrawal: a double-blind study. Jpn J Psychiatry 46 (1992) 733-739
67. Huang T.L. Lorazepam and diazepam rapidly relieve catatonic signs in patients with schizophrenia. Psychiatry Clin Neurosci 59 1 (2005) 52-55
68. Ichise M., Kim Y.J., Erami S.S., et al. Functional morphometry of the striatum in Parkinson's disease on three-dimensional surface display of 123I-beta-CIT SPECT data. J Nucl Med 40 4 (1999) 530-538
69. Inoue F., and Janikowski A.M. Withdrawal akinesia. J Neurol Neurosurg Psychiatry 44 (1981) 958
70. Jankovic J. Tardive syndromes and other drug-induced movement disorders. Clin Neuropharmacol 18 (1995) 197-214
71. Jellinger K. Overview of morphologic changes in Parkinson's disease. In: Yahr M.D., and Bergman K.J. (Eds). Advances in Neurology Vol. 45 (1986), Raven Press, New York 1-18
72. Jennings D.L., Seibyl J.P., Oakes D., et al. (123I) beta-CIT and single-photon emission computed tomographic imaging vs clinical evaluation in Parkinsonian syndrome: unmasking an early diagnosis. Arch Neurol 61 8 (2004) 1224-1229
73. Jensen K., and Amdisen A. Treatment of drug-induced parkinsonism: a comparison between UK-738, orphenadrine, and a placebo in a double blind study. Psychopharmacologia 192 (1964) 301-305
74. Jeste D.V., Lohr J.B., Eastham J.H., et al. Adverse neurobiological effects of long-term use of neuroleptics: human and animal studies. J Psychiatr Res 32 3-4 (1998) 201-214
75. Kelly J.T., and Abuzzahab Sr. F.S. The antiparkinson properties of amantadine in drug-induced parkinsonism. J Clin Pharmacol New Drugs 11 3 (1971) 211-214
76. Kelly J.T., Zimmermann R.L., Abuzzahab F.S., et al. A double-blind study of amantadine hydrochloride versus benztropine mesylate in drug-induced parkinsonism. Pharmacology 12 2 (1974) 65-73
77. Kennedy P.F., Hershon H.I., and McGuire R.J. Extrapyramidal disorders after prolonged phenothiazine therapy. Br J Psychiatry 118 (1971) 509-518
78. Kim J.H., and Byun H.J. Prevalence and characteristics of subjective akathisia, objective akathisia, and mixed akathisia in chronic schizophrenic subjects. Clin Neuropharmacol 26 6 (2003) 312-316
79. Klawans Jr. H.L., Bergen D., and Bruyn G.W. Prolonged drug-induced Parkinsonism. Confin Neurol 35 6 (1973) 368-377
80. Kuzuhara S. Drug-induced parkinsonism. Nippon Rinsho 55 1 (1997) 112-117
81. Kuzuhara S. Essential points to differentiate various diseases causing parkinsonism. Nippon Rinsho 58 10 (2000) 2049-2053
82. Kurz M., Hummer M., Oberbauer H., et al. Extrapyramidal side effects of clozapine and haloperidol. Psychopharmacology (Berl) 118 (1995) 52-56
83. Leopold N.A. Dysphagia in drug-induced parkinsonism: a case report. Dysphagia 11 2 (1996) 151-153
84. Llau M.E., Nguyen L., Senard J.M., et al. Drug-induced parkinsonian syndromes: a 10-year experience at a regional center of pharmaco-vigilance. Rev Neurol (Paris) 150 11 (1994) 757-762
85. Llau M.E., Senard J.M., Rascol O., et al. Movement disorders induced by drugs: experience at a pharmaco-vigilance center over five years. Therapie 50 5 (1995) 425-427
86. Lorenzo Bosquet C., Miquel Rodriguez F., Roca Bielsa I., et al. Differential diagnosis of parkinsonism using dopamine transporters brain SPECT. Med Clin (Barc) 122 9 (2004) 325-328
87. Lucetti C., Nuti A., Pavese N., et al. Flunarizine in migraine prophylaxis: predictive factors for a positive response. Cephalagia 18 (1998) 349-352
88. Luchins D.J., Jackman H., and Meltzer H.Y. Lateral ventricular size and drug-induced Parkinsonism. Psychiatry Res 9 1 (1983) 9-16
89. Lyne J., Kelly B.D., and O'Connor W.T. Schizophrenia: a review of neuropharmacology. Ir J Med Sci 173 (2004) 155-159
90. Magnus R.V. A comparison of biperiden hydrochloride (Akineton) and benzhexol (Artane) in the treatment of drug-induced Parkinsonism. J Int Med Res 8 5 (1980) 343-346
91. Mamo D.C., Sweet R.A., and Keshavan M.S. Managing antipsychotic-induced parkinsonism. Drug Saf 20 (1999) 269-275
92. Marek K.L., Seibyl J.P., Zoghbi S.S., et al. 123-ICIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease. Neurology 46 (1996) 231-237
93. Marinus J., Ramaker C., Van Hilten J.J., et al. Health related quality of life in Parkinson's disease: a systematic review of disease specific instruments. J Neurol Neurosurg Psychiatry 72 (2002) 241-248
94. Marshall V., and Grosset D. Role of dopamine transporter imaging in routine clinical practice. Mov Disord 18 12 (2003) 1415-1423
95. Marti Masso J.F., and Poza J.J. Drug-induced or aggravated parkinsonism: clinical signs and the changing pattern of implicated drugs. Neurologia 11 (1996) 10-15
96. Marti-Masso J.F., and Poza J.J. Cinnarizine-induced parkinsonism: ten years later. Mov Disord 13 (1998) 453-456
97. Marti Masso J.F., Carrera N., and Urtasun M. Drug-induced parkinsonism: a growing list. Mov Disord 8 1 (1993) 125
98. Melamed E., Achiron A., Shapira A., et al. Persistent and progressive parkinsonism after discontinuation of chronic neuroleptic therapy: an additional tardive syndrome?. Clin Neuropharmacol 14 3 (1991) 273-278
99. Mena M.A., Garcia de Yebenes M.J., Tabernero C., et al. Effects of calcium antagonists on the dopamine system. Clin Neuropharmacol 18 (1995) 410-426
100. Metzer W.S., Newton J.E., Steele R.W., et al. HLA antigens in drug-induced parkinsonism. Mov Disord 4 2 (1989) 121-128
101. Metzer W.S., Paige S.R., and Newton J.E. Inefficacy of propranolol in attenuation of drug-induced parkinsonian tremor. Mov Disord 8 1 (1993) 43-46
102. Micheli F., Pardal M.F., Gatto M., et al. Flunarizine- and cinnarizine-induced extrapyramidal reactions. Neurology 37 (1987) 881-884
103. Micheli F., Fernandez Pardal M., Gatto M., et al. Bruxism secondary to chronic antidopaminergic drug exposure. Clin Neuropharmacol 16 4 (1993) 315-323
104. Micheli F.E., Pardal M.M., Giannaula R., et al. Movement disorders and depression due to flunarizine and cinnarizine. Mov Disord 4 (1989) 139-146
105. Moghal S., Rajput A.H., Meleth R., et al. Prevalence of movement disorders in institutionalized elderly. Neuroepidemiology 14 6 (1995) 297-300
106. Moleman P., Schmitz P.J., and Ladee G.A. Extrapyramidal side effects and oral haloperidol: an analysis of explanatory patient and treatment characteristics. J Clin Psychiatry 43 (1982) 492-496
107. Morris J.C., Drazner M., Fulling K., et al. Clinical and pathological aspects of parkinsonism in Alzheimer's disease. A role for extranigral factors?. Arch Neurol 46 6 (1989) 651-657
108. Naito Y., and Kuzuhara S. Essential points to differentiate various diseases causing parkinsonism. Nippon Rinsho 62 9 (2004) 1608-1616
109. Negrotti A., and Calzetti S. A long-term follow-up study of cinnarizine- and flunarizine-induced parkinsonism. Mov Disord 12 (1997) 107-110
110. Negrotti A., Calzetti S., and Sasso E. Calcium-entry blockers-induced parkinsonism: possible role of inherited susceptibility. Neurotoxicology 13 1 (1992) 261-264
111. Nguyen N., Pradel V., Micallef J., et al. Drug-induced parkinson syndromes. Therapie 59 1 (2004) 105-112
112. Offen D., Ziv I., Gorodin S., et al. Dopamine-induced programmedcell death in mouse thymocytes. Biochem Biophys Acta 1268 (1995) 171-177
113. Ohashi K., Hamamura T., Lee Y., et al. Propranolol attenuates haloperidol-induced Fos expression in discrete regions of rat brain: possible brain regions responsible for akathisia. Brain Res 802 (1998) 134-140
114. O'Shea E., and Colado M.I. Is frequent dosing with ecstasy a risky business for dopamine-containing neurons?. Trends Pharmacol Sci 24 (2003) 272-274
115. O'Suilleabhain P., and Giller C. Rapidly progressive parkinsonism in a self-reported user of ecstasy and other drugs. Mov Disord 18 11 (2003) 1378-1381
116. Pina Latorre M.A., Modrego P.J., Rodilla F., et al. Parkinsonism and Parkinson's disease associated with long-term administration of sertraline. J Clin Pharm Ther 26 (2001) 111-112
117. Pitágoras de Mattos J., Zuma de Rosso A.L., Branco Corrêa R., et al. Movement disorders in 28 HIV-infected patients. Arq Neuropsiquiatr 60 (2002) 525-530
118. Prosser E.S., Csernansky J.G., Kaplan J., et al. Depression, parkinsonian symptoms, and negative symptoms in schizophrenics treated with neuroleptics. J Nerv Ment Dis 175 2 (1987) 100-105
119. Prueter C., Habermeyer B., Norra C., et al. Akathisia as a side effect of antipsychotic treatment with quetiapine in a patient with Parkinson's disease. Mov Disord 18 (2003) 712-713
120. Quinn N.P. Parkinsonism: recognition and differential diagnosis. BMJ 310; 44 (1995) 7-452
121. Rajput A.H., Rozdilsky B., and Hornykienicz O. Reversible drug-induced parkinsonism, clinicopathologic study of two cases. Neurology 39 (1982) 644-646
122. Rajput A.H., Offord K.P., Beard C.M., et al. Epidemiology of parkinsonism: incidence, classification, and mortality. Ann Neurol 16 (1984) 278-282
123. Rajput A.H., Pahwa R., Pahwa P., et al. A Prognostic significance of the onset mode in parkinsonism. Neurology 43 4 (1993) 829-830
124. Reyes M.G., Faraldi F., Senseng C.S., et al. Nigral degeneration in acquired immune deficiency syndrome (AIDS). Acta Neuropathol (Berl) 82 (1991) 39-44
125. Robertson G.S., and Fibiger H.C. Neuroleptics increase c-fos expression in the forebrain: contrasting effects of haloperidol and clozapine. Neuroscience 46 (1992) 315-328
126. Rollema H., Skolnik M., D'Engelbronner J., et al. P(C)-like neurotoxicity of a pyridinium metabolite derived from haloperidol: in vivo microanalysis and in vitro mitochondrial studies. J Pharmacol Exp Ther 268 (1994) 380-387
127. Rosen A. Drug-induced parkinsonism and its treatment with Akineton. Ther Umsch 20 (1963) 9-12
128. Saltz B.L., Woerner M.G., Robinson D.G., et al. Side effects of antipsychotic drugs. Avoiding and minimizing their impact in elderly patients. Postgrad Med 107 2 (2000) 169-178
129. Sandyk R. Cigarette smoking: effects on cognitive functions and drug-induced parkinsonism in chronic schizophrenia. Int J Neurosci 70 3-4 (1993) 193-197
130. Sandyk R., and Kay S.R. "Positive" and "negative" movement disorders in schizophrenia. Int J Neurosci 66 3-4 (1992) 143-151
131. Schmidt W.J., Mayerhofer A., Meyer A., et al. Ecstasy counteracts catalepsy in rats, an anti-parkinsonian effect?. Neurosci Lett 330 (2002) 251-254
132. Sethi K.D., and Zamrini E.Y. Asymmetry in clinical features of drug-induced parkinsonism. J Neuropsychiatry Clin Neurosci 2 1 (1990) 64-66
133. Spigset O. Adverse reactions of selective serotonin reuptake inhibitors: reports from a spontaneous reporting system. Drug Saf 20 (1999) 277-287
134. Stacy M., and Jankovic J. Tardive tremor. Mov Disord 7 (1992) 53-57
135. Steck H. Le syndrome extrapyramidal et diencephalique au cours de traitments au Largactril et au serpasil. Ann Med Psychol 2 (1954) 737-744
136. Strous R.D., Alvir J.M., Robinson D., et al. Premorbid functioning in schizophrenia: relation to baseline symptoms, treatment response, and medication side effects. Schizophr Bull 30 2 (2004) 265-278
137. Sulzer D., Maidment N.T., and Rayport S. Amphetamine and other weak bases act to promote reverse transport of dopamine in ventral midbrain neurons. J Neurochem 60 (1993) 527-535
138. Teive H.A., Troiano A.R., Germiniani F.M., et al. Flunarizine and cinnarizine-induced parkinsonism: a historical and clinical analysis. Parkinsonism Relat Disord 10 4 (2004) 243-245
139. Terland O., and Flatmark T. Drug-induced parkinsonism: cinnarizine and flunarizine are potent uncouplers of the vacuolar H+-ATPase in catecholamine storage vesicles. Neuropharmacology 38 (1999) 879-882
140. Tolosa E., Coelho M., and Gallardo M. DAT imaging in drug-induced and psychogenic parkinsonism. Mov Disord 18 Suppl 7 (2003) S28-S33
141. Uhnbrand L., and Faurbye A. Reversible and irreversible dyskinesias after treatment with perphenazine, chlorpromazine, reserpine and electroconvulsive therapy. Psychopharmacology (Berl) 1 (1969) 408-418
142. Vaccari A., Saba P., and Gessa G. Potent, extra-channel influence of several calcium-channel modulators on striatal binding of [3H]tyramine. Neurochem Res 18 (1993) 1125-1130
143. Van der Heijden F.M., Tuinier S., Arts N.J., et al. Catatonia: disappeared or under-diagnosed?. Psychopathology 38 (2005) 3-8
144. Veitch K., and Hue L. Flunarizine and cinnarizine inhibit mitochondrial complexes I and II: possible implication for parkinsonism. Mol Pharmacol 45 (1994) 158-163
145. Wada Y., and Yamaguchi N. The rabbit syndrome and antiparkinsonian medication in schizophrenic patients. Neuropsychobiology 25 3 (1992) 149-152
146. Weiden P.J., Mann J.J., Haas G., et al. Clinical nonrecognition of neuroleptic-induced movement disorders: a cautionary study. Am J Psychiatry 144 (1987) 1148-1153
147. Yamasue H., Fukui T., Fukuda R., et al. Drug-induced parkinsonism in relation to choline-containing compounds measured by 1H-MR spectroscopy in putamen of chronically medicated patients with schizophrenia. Int J Neuropsychopharmacol 6 4 (2003) 353-360
148. Ziv I., Melamed E., Nardi N., et al. Dopamine induces apoptosis-like cell death in cultured chick sympathetic neurons-a possible novel pathogenic mechanism in Parkinson's disease. Neurosci Lett 170 (1995) 136-140